NCT06035497 2026-04-06A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Bristol-Myers SquibbPhase 1/2 Active not recruiting85 enrolled
NCT06854653 2026-03-31A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLPrescient Therapeutics, Ltd.Phase 2 Recruiting115 enrolled